Back to the Xenexus Pharmaceutical Home Page


Xenexus Pharmaceuticals - Developing innovative drugs for the treatment of neurological disorders Xenexus Pharmaceuticals - Developing innovative drugs for the treatment of neurological disorders Xenexus Pharmaceuticals - Developing innovative drugs for the treatment of neurological disorders Xenexus Pharmaceuticals - Developing innovative drugs for the treatment of neurological disorders

Management

Dr Michael L. Selley, PhD, FRACI

Chairman and Chief Executive Officer


Dr Michael L. Selley - Chairman and Chief Executive Officer

Dr Selley has considerable experience in pharmaceutical research and development. He was the founder of Angiogen Pharmaceuticals Pty. Ltd., Xenexus Pharmaceuticals Pty. Ltd., founder and Chief Scientific Officer of Nuon Therapeutics, Inc. and cofounder of Bioatrix Pty. Ltd. Dr Selley previously served as Chief of Staff to the Minister for Science and Technology in the Australian Parliament and held academic appointments in the John Curtin School of Medical Research at the Australian National University. He has worked in the international pharmaceutical industry in a number of roles, including drug discovery, toxicology, and clinical trials.

Robert J. Scott, MBA

Chief Operating Officer

Robert (Rob) Scott has nearly 20 years’ experience in delivering trade, transaction and advisory services to pharmaceutical and medical technology companies entering China. His specialist areas include mergers and acquisitions, business planning and venture capital raising. Mr. Scott was previously responsible for developing the Ernst & Young Queensland practice’s China strategy in his role as State Leader, China Business Group.

Scientific Advisers

Dr Scott L. Friedman, MD

Dr Scott L. Friedman is Fishberg Professor of Medicine, Professor of Pharmacology and Systems Therapeutics, Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai Hospital, New York. Dr Friedman is responsible for the discovery of a novel tumour suppressor gene, KLF6 that is inactivated in a number of human cancers, including primary liver cancer. He has performed pioneering research into the underlying causes of scarring, or fibrosis, associated with chronic liver disease, which affects millions worldwide. He was among the first to isolate and characterise the hepatic stellate cell, which is the key cell type responsible for scar production in liver.

Dr George Perry, PhD

Dr George Perry is Professor and Chief Scientist of the Brain Health Consortium and the Semmes Foundation Distinguished University Chair in Neurobiology in the Department of Biology in the University of Texas at San Antonio. Dr Perry’s studies are focused on the mechanism of formation and physiological consequences of the cytopathology of Alzheimer’s disease.






by Echidna Web Design. Click here to visit.